Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics

Nature

Volumn 432, Issue 7013, 2004, Pages 59-67

  Xia, Tsan ^a   Takagi, Junichi ^a,c   Coller, Barry S ^b   Wang, Jia Huai ^a   Springer, Timothy A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGY; CELL MEMBRANES; CRYSTAL STRUCTURE;

ALLOSTERY; HYBRID DOMAINS; METAZOA; PLATELET INTEGRIN;

ADHESION;

ALPHAIIB BETA3 INTEGRIN; AMINO ACID; ANTICOAGULANT AGENT; FIBRINOGEN; FIBRINOGEN ANTAGONIST; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT 10E5; LIGAND; PLEXIN; SEMAPHORIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2;

BIOLOGY;

ALLOSTERISM; ALPHA HELIX; AMINO ACID SEQUENCE; BINDING SITE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; METAL BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; REVIEW; STRUCTURE ANALYSIS; THROMBOCYTE;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; AMINO ACID SEQUENCE; BIOMIMETIC MATERIALS; CALCIUM; CRYSTALLOGRAPHY, X-RAY; FIBRINOGEN; LIGANDS; MAGNESIUM; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY;

METAZOA;

EID: 8544259562     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02976     Document Type: Review

References (50)

1. Hughes, P. E. & Pfaff, M. Integrin affinity modulation. Trends Cell Biol. 8, 359-364 (1998).
2. Takagi, J. & Springer, T. A. Integrin activation and structural rearrangement. Immunol. Rev. 186, 141-163 (2002).
3. Takagi, J., Petre, B. M., Walz, T. & Springer, T. A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110, 599-611 (2002).
4. Springer, T. A. & Wang, J.-h. in Cell Surface Receptors (ed. Garcia, K. C.) (Elsevier, San Diego, 2004).
5. Coller, B. S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J. Clin. Invest. 99, 1467-1471 (1997).
6. Takagi, J., Strokovich, K., Springer, T. A. & Walz, T. Structure of integrin α5β1 in complex with fibronectin. EMBO J. 22, 4607-4615 (2003).
7. Xiong, J.-P. et al. Crystal structure of the extracellular segment of integrin αVβ3. Science 294, 339-345 (2001).
8. Xiong, J. P. et al. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155 (2002).
9. Luo, B.-H., Springer, T. A. & Takagi, J. Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand. Proc. Natl Acad. Sci. USA 100, 2403-2408 (2003).
10. Luo, B.-H., Strokovich, K., Walz, T., Springer, T. A. & Takagi, J. Allosteric β1 integrin antibodies that stabilize the low affinity state by preventing the swing-out of the hybrid domain. J. Biol. Chem. 279, 27466-27471 (2004).
11. Luo, B.-H., Springer, T. A. & Takagi, J. High affinity ligand binding by integrins does not involve head separation. J. Biol. Chem. 278, 17185-17189 (2003).
12. Mould, A. P. et al. Structure of an integrin-ligand complex deduced from solution X-ray scattering and site-directed mutagenesis. J. Biol. Chem. 278, 39993-39999 (2003).
13. Mould, A. P. et al. Conformational changes in the integrin βA domain provide a mechanism for signal transduction via hybrid domain movement. J. Biol. Chem. 278, 17028-17035 (2003).
14. Du, X. et al. Ligands "activate" integrin αIIbβ3 (platelet GPIIb-IIIa). Cell 65, 409-416 (1991).
15. Adair, B. D. & Yeager, M. Three-dimensional model of the human platelet integrin αIIbβ3 based on electron cryomicroscopy and X-ray crystallography. Proc. Natl Acad. Sci. USA 99, 14059-14064 (2002).
16. Luo, B.-H., Springer, T. A. & Takagi, J. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol. 2, 776-786 (2004).
17. 3 "inside-out" activation as regulated by its cytoplasmic face. Cell 110, 587-597 (2002).
18. Kim, M., Carman, C. V. & Springer, T. A. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 301, 1720-1725 (2003).
19. Coller, B. S., Peerschke, E. I., Scudder, L. E. & Sullivan, C. A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. 72, 325-338 (1983).
20. Kamata, T., Tieu, K. K., Springer, T. A. & Takada, Y. Amino acid residues in the αIIb subunit that are critical for ligand binding to integrin αIIbβ3 are clustered in the β-propeller model. J. Biol. Chem. 276, 44275-44283 (2001).
21. Artoni, A. et al. The specificity determining loop and α helix 1 on human integrin β3 determine the binding of murine monoclonal antigbody 7E3 to αIIbβ3: implications for the mechanism of integrin activation. Proc. Natl Acad. Sci. USA (in the press) (2004).
22. Zavortink, M., Bunch, T. A. & Brower, D. L. Functional properties of alternatively spliced forms of the Drosphila PS2 integrin α subunit. Cell Adhes. Commun. 1, 251-264 (1993).
23. von der Mark, H. et al. Alternative splice variants of α7β1 integrin selectivity recognize different laminin isoforms. J. Biol. Chem. 277, 6012-6016 (2002).
24. Springer, T. A. Predicted and experimental structures of integrins and β-propellers. Curr. Opin. Struct. Biol. 12, 802-813 (2002).
25. Lee, J.-O., Rieu, P., Arnaout, M. A. & Liddington, R. Crystal structure of the A domain from the α subunit of integrin CR3 (CDIIb/CD18). Cell 80, 631-638 (1995).
26. Lee, J.-O., Bankston, L. A., Arnaout, M. A. & Liddington, R. C. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure 3, 1333-1340 (1995).
27. Shimaoka, M. et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112, 99-111 (2003).
28. Scarborough, R. M. & Gretler, D. D. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J. Med. Chem. 43, 3453-3473 (2000).
29. Gottschalk, K. E. & Kessler, H. The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew. Chem. Int. Edn Engl. 41, 3767-3774 (2002).
30. Egbertson, M. S. et al. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J. Med. Chem. 42, 2409-2421 (1999).
31. Scarborough, R. M. et al. Design of potent and specific integrin antagonists. J. Biol. Chem. 268, 1066-1073 (1993).
32. Mould, A. P. et al. Integrin activation involves a conformational change in the α1 helix of the β subunit A-domain. J. Biol. Chem. 277, 19800-19805 (2002).
33. Chen, J. F., Salas, A. & Springer, T. A. Bistable regulation of integrin adhesiveness by a bipolar metal ion cluster. Nature Struct. Biol. 10, 995-1001 (2003).
34. Perutz, M. F. Mechanisms of cooperativity and allosteric regulation in proteins. Q. Rev. Biophys. 22, 139-237 (1989).
35. Love, C. A. et al. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nature Struct. Biol. 10, 843-848 (2003).
36. Bork, P., Doerks, T., Springer, T. A. & Snel, B. Domains in plexins: Links to integrins and transcription factors. Trends Biochem. Sci. 24, 261-263 (1999).
37. Calvete, J. J., Henschen, A. & González-Rodríguez, J. Assignment of disulphide bonds in human platelet GPIIIa. A disulphide pattern for the β-subunits of the integrin family. Biochem. J. 274, 63-71 (1991).
38. Beglova, N., Blacklow, S. C., Takagi, J. & Springer, T. A. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nature Struct. Biol. 9, 282-287 (2002).
39. Newman, P. J., Derbes, R. S. & Aster, R. H. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 83, 1778-1781 (1989).
40. Watkins, N. A. et al. HPA-1a phenotype-genotype discrepancy reveals a naturally occurring Arg93Gln substitution in the platelet β3 integrin that disrupts the HPA-1a epitope. Blood 99, 1833-1839 (2002).
41. Kunicki, T. J. et al. The P1A alloantigen system is a sensitive indicator of the structural integrity of the amino-terminal domain of the human integrin β3 subunit. Blood Cells Mol. Dis. 21, 131-141 (1995).
42. Chen, J. F. et al. The relative influence of metal ion binding sites in the I-like domain and the interface with the hybrid domain on rolling and firm adhesion by integrin α4β7. J. Biol. Chem. (in the press).
43. Luo, B.-H., Takagi, J. & Springer, T. A. Locking the β3 integrin I-like domain into high and low affinity conformations with disulfides. J. Biol. Chem. 279, 10215-10221 (2004).
44. Yang, W., Shimaoka, M., Chen, J. F. & Springer, T. A. Activation of integrin β subunit I-like domains by one-turn C-terminal α-helix deletions. Proc. Natl Acad. Sci. USA 101, 2333-2338 (2004).
45. Takagi, J., Erickson, H. P. & Springer, T. A. C-terminal opening mimics "inside-out" activation of integrin α5β1. Nature Struct. Biol. 8, 412-416 (2001).
46. Esnouf, R. M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15, 132-138 (1997).
47. Merritt, E. A. & Murphy, M. E. P. Raster 3D version 2.0: a program for photorealistic graphics. Acta Crystallogr. D 50, 869-873 (1994).
48. Carson, M. Ribbons. Methods Enzymol. 277, 493-505 (1997).
49. Puzon-McLaughlin, W., Kamata, T. & Takada, Y. Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrin αIIbβ3. J. Biol. Chem. 275, 7795-7802 (2000).
50. IIbβ3 is dependent on a MIDAS-like domain in the β3 subunit. J. Biol. Chem. 271, 21978-21984 (1996).